Pipeline
A focused pipeline of innovative gene therapies.
We are advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.
- uniQure Proprietary programs
- CSL Behring partnership
- Program Name
- Preclinical
- Phase 1/2
- Phase 3
Indications
-
Hemophilia B etranacogene dezaparvovec (AMT‑061)
-
Huntington’s Disease (AMT-130)
-
Fabry Disease (AMT‑191)
-
Temporal Lobe Epilepsy (AMT-260)
-
Other undisclosed programs